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Introduction 
Heparin is a negatively charged non-branching muco- 
polysaccharide of glycosaminoglycan type. Commer- 
cially available preparations are obtained from porcine 
intestinal mucosa or bovine lung. These preparations 
are heterogeneous and contain contaminating sub- 
stances. The molecular weight of heparin chains vary 
from 3000 to 60 000 Daltons, but in commercial 
preparations are usually 15 000 to 20 000 DaltonsJ "2 
The low molecular weight (LMW) heparins have an 
average molecular weight of 3000 to 10 000 Daltons. 
Semisynthetic heparinoid, Org 10172 (Orgaran, Lomo- 
paran) contains only 3% LMW heparin with the 
remaining bulk of this material consisting of other 
glycosaminoglycans. 3 
The anticoagulant effect of heparin is dependent on 
its ability to reversibly bind antithrombin III and to 
catalyse its inactivation of thrombin, factor Xa, IXa, 
XIa, XIIa and prekallikrein. Elimination kinetics are 
principally mediated by a non saturable mechanisms. 
Heparin is metabolised in the liver but elimination 
half-life is increased in patients with kidney disease, 
suggestin§ a significant renal component to 
clearance. 
The ability of heparin to induce thrombocytopenia 
(heparin induced thrombocytopenia, HIT) after an 
intravenous injection was recognised in animals in 
19394 and in man in 1948. 5Thromboembolic complica- 
tion resulting from heparin treatment was first 
re~orted in 1958 by Weismann and Tobin. 6 Roberts et 
al/ described several cases of peripheral arterial 
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Based on the clinical features and pathophysiological 
mechanisms two types of heparin induced thrombocy- 
topenia (HIT) have been ident.ified. 9-15 Type I HIT is 
non-immune (non-idiosyncratic) and is caused by the 
ability of heparin to increase the platelets response to 
aggregating stimuli. It has a rapid onset, usually 
within 1-5 days after the initiation of heparin therapy. 
Although, platelet counts may fall significantly they 
usually remain between 100 000 to 150 000/mm 3 and 
typically return to normal values within i to 5 days in 
spite of continued heparin therapy, n'16-~s The inci- 
dence of this mild form of HIT is about 10-20%. 19'2° 
Thus, this type of HIT is probably quite common, but 
it is not associated with any detrimental effects and 
therefore rarely noted clinically. ~5 
Type II HIT (idiosyncratic) is more serious and is 
frequently associated with limb and life threatening 
complications. 18'21-23 The incidence of type II HIT is 
subject o debate with estimates ranging from negli- 
gible to 30% 9"21'23-26 Approximately 107o of patients 
with type II HIT will develop thromboembolic compli- 
cations (TEC). 12'27-32 Some authors estimate that the 
risk of TEC in patients who become thrombocytopenic 
emboli occurring in patients being treated with hepa- 
rin and suggested that it might be caused by an 
immunologically mediated platelet aggregation. 
Rhodes et al. 8 found heparin dependent complement 
fixing activity in the gamma G globulin fraction of 
serum in several patients. Subsequently, the patho- 
physiologic mechanisms and the clinical features of 
HIT and thrombosis have been defined more dearly. 
Clinical Features and Incidence 
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may be as high as 20% 9 or even higher. 33 Based on the 
review of 22 prospective studies Schmitt and Adelman 
estimated the incidence of HIT with TEC to be less 
than 1%, 24 yet, they pointed out that there were no 
adequately designed studies to estimate the true 
incidence of HIT-related thrombosis or haemorrhage. 
In the reported cases, more than 90% of patients 
with severe HIT (platelet counts < 50 000 mm 3) and 
about 95% of patients with HIT and TEC developed 
the syndrome after 6 days or more after initiation of 
heparin treatment. 34However, if the patient has been 
previously exposed to heparin, thrombocytopenia 
may occur within hours or days following re-expo- 
sure. 9'21'35 HIT occur in all age groups including 
young children and the newborn. 36'37 
Type II HIT is characterised by marked thrombocy- 
topenia with platelet counts often < 50 000 mm 3. 
Platelet counts usually recover within 5 to 6 days after 
cessation of heparin treatment, but sometimes the 
recovery may be delayed for up to 6 weeks. 38 TEC are 
always accompanied by a fall in platelet counts, but 
thrombocytopenic levels are not always reached. 33'39"4° 
In general, the lower the platelet count, the higher the 
risk of TEC. 41 The platelet counts in HIT cases with 
TEC is usually 40-60 000/mm 3, but platelets counts as 
low as 5000/mm 3 have been reported. 9'27"42 Global 
activation of the coagulation cascade may occur 
during an acute thrombogenic episode. 43 One of the 
first symptoms of impending TEC can be unexplained 
abdominal or lumbar pain, 42'44 and/or the develop- 
ment of heparin resistance. 8'21'35 Inability to maintain 
an adequate l vel of anticoagulation despite increased 
doses of heparin may be caused by release of platelet 
factor 4, which is heparin neutralising factory "35'46-~8 
Heparin induced skin necrosis may also precede the 
development of HIT with TEC. 47-5° 
A wide clinical spectrum of thrombotic omplica- 
tions has been described in HIT. The most common 
events include lower limb arterial thrombo- 
sis, 6"7'21'22"26'35'45 myocardial infarction, 1°'35'45 thrombo- 
tic cerebrovascular ccidents. 22'33'35'49 Less frequently 
49 50 reported complications includes skin necrosis, " 
upper limb arterial occlusions, 51 renal artery and vein 
thrombosis, 6'52'53 mesenteric ischaemia, 2L22'39 spinal 
artery thrombosis, 13 arterial graft thrombosis, 21'54 
spleen infarction, 22 adrenal thrombosis and/or haem- 
orrhage resulting in acute or chronic adrenal insuffi- 
ciency, 55"56 and aorta thrombosis with multiorgan 
failure. 57 Extension of venous thrombosis with pulmo- 
nary embolism and cases of phlegmasia cerulea 
dolens requiring amputation have also been 
reported. 1°'13'35'58-6° Thrombosis is most often loc- 
alised in the area with underlying vascular disease. 9 
Bleeding complications ofHIT are less frequent than 
thrombotic omplications, but serious bleeding may 
occur including retroperitoneal, intracere- 
bral, 14"21"32'35'45 gastrointestinal and postoperative 
haemorrhage. 22'23 Disseminated intravascular coagu- 
lation (DIC) has been occasionally reported. 27'42"61 
The morbidity and mortality of HIT is dramatic. 
Patients are often critically ill at the time of the 
thrombotic episode as reflected by the reported 
morbidity rates of 22-80% and mortality rates of 
12-30%. 21'23 The frequency of TEC in HIT can be 
reduced by careful patient monitoring, but mortality 
rates remain high once the complication occurs. 23 
Contributing Factors 
Source of heparin 
Both bovine lung and porcine intestinal mucosal 
heparins have been implicated in most cases of HIT. 
However, drug induced thrombocytopenia and arte- 
rial thrombosis has also been diagnosed in patients 
treated with LMW heparins, 62'63 pentosan polysul- 
phate, 64 and with a drug which resembles chondroitin 
sulfate (Arteparon). 65 It is not clear if heparinoid (Org 
10172) can initiate type II HIT, but when given to 
patients who already have HIT caused by standard 
heparin, it can reactivate the syndrome. 34'61'62'66'67 
Several prospective randomised studies have been 
conducted to compare the incidence of HIT caused by 
bovine and porcine heparin. 11'12'17"20'25'28'31-33"68 The 
majority of these studies revealed a higher incidence 
of HIT after administration of bovine heparin. War- 
kentin and Kelton 9"34 analysed five prospective rando- 
mised studies 17"25'28'31'68 and found that the incidence 
of HIT was approximately 1% for porcine mucosal and 
5% for bovine lung heparin. Schmitt and Adelman 24 
reported that the pooled incidence of HIT in studies 
requiring a reproducibly lower platelet count 
(< 100 000 mm 3) was 1.1% with intravenous porcine 
heparin and 2.9% with intravenous bovine heparin. 
The differences in chemical composition, platelet 
aggregating properties and purity of heparin from 
various sources may explain the difference. 
Dose and route of administration 
HIT occurs in patients treated with either therapeutic 
or prophylactic doses of heparin. 7'23'69"7° The risk of 
HIT appears to be significantly lower with subcuta- 
neous heparin than that seen with intravenous ther- 
apy. 24 However, type II HIT can be caused by small 
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amounts of heparin used in heparin flushes (250-500 
units per day) 29"39'71-73 and by heparin present on 
heparin-coated pulmonary artery catheters. 74'75 
Thromboembolic and haemorrhagic complications of 
HIT are more common in patients receiving high-dose 
heparin. 23,3° 
Pathogenesis 
The pathogenesis of HIT is not entirely understood, 
but available data suggest hat there are different 
mechanisms for type I and type II HIT. In both types, 
thrombocytopenia does not seem to be due to platelet 
lysis but rather aggregation. The findings supporting 
this theory is that both discontinuation of heparin 
therapy or addition of protamine cause a recovery of 
platelet counts, which is too rapid to be due to 
replacement from the bone marrow. In addition, 
thrombi found in the arteries and veins of patients 
with HIT and TEC are of "white clot" t~pe i.e. mainly 
composed of platelet aggregates. 6'7'42"44"54'61'75 It has 
been suggested that HIT is a manifestation of DIC 
caused by heparin. 27'47'76'77 However, in the majority 
of HIT cases DIC is not diagnosed and if it is, it can 
usually be attributed to the underlying 
disease.14,21,35,43,52, 7~80
Type I HIT 
Heparin can cause a mild platelet activation and 
aggregation in platelet rich plasma obtained from 
animals and persons 4'5 who have never been exposed 
to heparin. 18'81"82 This in vitro platelet activation is 
more prominent with bovine heparin than with 
porcine heparin and is significantly reduced or even 
absent with LMW heparins and heparinoid. 34's3 Hepa- 
rin binds to platelets in a specific and saturable fashion 
with sufficiently low Kd for binding to occur at 
84 85 therapeutic heparin concentrations. ' The greatest 
amount of binding has been found for heparin 
fractions with high molecular weight and most exten- 
84 sive sulphation. It has been also shown that heparin 
enhances the effect of platelet aggregation by other 
stimuli such as ADP, arachidonic acid, immune com- 
plexes and bacterial products, 6 In addition, heparin at 
therapeutic concentrations incubated with hyperag- 
gregable platelets from patients with prosthetic valves 
or severe peripheral vascular disease sT's8 induced 
significant platelet aggregation i vitro. 
The proaggregatory properties of heparin in vitro 
disappear after neutralisation with protamine sul- 
phate or digestion with heparinase. 7s'89'9° Thus, the 
effect of heparin on platelets is presumably accom- 
plished by heparin itself, rather than a contaminant. 
This direct effect of heparin on platelets occurs in 
humans in vivo as well 5'2°'44 and explains the lack of 
demonstrable circulatory antiplatelet antibodies typ- 
ical for type I HIT. It has been also suggested that type 
I HIT may be coincidental not causally related to 
heparin itself is or may partially result from the 
technical error of electronic platelet counters. 34
Type II HIT 
Both clinical and laboratory evidence indicate that the 
severe, delayed onset heparin-induced thrombocyto- 
penia is mediated by an immune mechanism. The 
evidence includes: (a) thrombocytopenia usually 
occurs 6-12 days after the first administration of 
heparin; (b) thrombocytopenia may occur within 
hours in patients who have previously been exposed 
to heparinl°'35; (c) a platelet aggregating factor is 
present in the IgG and IgM fractions of 
serum 8'45'52'79'91, (d) the platelet associated IgG frac- 
tion is often elevated uring the thrombocytopenic 
phase. Several different mechanisms of interaction 
between platelets, IgG and heparin have been postu- 
8 29 45 79 80 92 93 93 lated. ' . . . . .  Kelton et al. suggested that hepa- 
rin is first bound to the platelet surface by platelet 
proteins, subsequently anti-heparin IgG binds to the 
antigenic determinants on the heparin molecule. 
Finally9 IgG binds to the platelets via Fc II receptors, 
which initiates platelet activation. This activation can 
be blocked in vitro by monoclonal antibodies pecific 
for the platelet Fc receptor. 93 Lynch and Howe 8° 
proposed that heparin binds to platelets, and by its 
negative charge induces a change in the platelet 
membrane, exposing an immunogenic substance. 
Anderson 94 postulated that heparin has two distinct 
roles in type II HIT. First, heparin binds to the platelet 
surface, exposing new antigenic determinants which 
elicits antibody binding and platelet activation 
through Fc receptor mediated platelet-platelet inter- 
action. In addition, heparin exerts a non-specific 
proaggregatory effect which is related to its size and 
negative charge. Recently9 Amiral et al. 95 proposed the 
involvement ofplatelet factor 4 in the platelet binding 
of heparin-dependent antibodies. Visentin et al. 91 
confirmed these results and found that platelet activat- 
ing, heparin-induced antibodies are specific for plate- 
let factor 4/heparin complexes. 
The duration of heparin-dependent IgG is 
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unknown, but once heparin therapy is discontinued 
antibody levels slowly decrease over a period of 
several months, with concomitant loss of heEarin- 
induced platelet aggregation in vitro. 18"29"48"59"71"90"96 
Several patients have been re-exposed toheparin after 
1 to 4 months and have not developed recurrent 
HIT. 8"16"21"45'96 However, persistent heparin sensitivity 
28 months and 7 years respectively after ecovery from 
HIT have been reported. 23'97 Early re-exposure to 
heparin after HIT may sometimes be disastrous, in 
three reported cases the patients developed massive 
pulmonary embolism and died within 30 min. 13'~8"5° 
Pathophysiology of heparin induced thrombosis 
The pathophysiology of heparin induced thrombosis 
is not well known. There is no clinical sign, nor 
laboratory test which allows prediction of thrombem- 
bolic complication i patients with HIT. Some clinical 
observations indicate that thrombi occur more fre- 
quently at sites of pre-existing vascular disease or 
endothelial damage, caused by balloon catheter used 
for thromboembolectomy or recent arterial puncture 
43 58 for heart catheterisation. • Thus, the integrity of the 
vascular endothelium could be an important factor in 
the development of TEC in HIT. Cines et al. 98 
demonstrated that heparin antibodies bind to cultured 
endothelial cells and promote expression of tissue 
factor in the cells in the absence of heparin. Recently, 
Visentin et al. 91 suggested that antibodies associated 
with HIT may react with platelet factor 4 complexed 
with heparan sulfate on the surface of endothelial cells 
leading to antibody-mediated endothelial injury and a 
predilection to thrombosis. 
Diagnosis 
HIT should be suspected in patients with thrombocy- 
topenia which occurs during heparin therapy and 
resolves after withdrawal of heparin. It is, however, 
important to remember that HIT is primarily a clinical 
diagnosis of exclusion, particularly in patients who 
also receive several other drugs and/or have co- 
morbid conditions uch as sepsis, disseminated intra- 
vascular coagulation, idiopathic thrombocytopenia 
purpura and bone marrow failure. 
Coagulation tests may distinguish eparin-induced 
platelet aggregation from other clotting disorders, 
since in HIT fibrinogen and fibrin split product levels 
as well as prothrombin time are usually normalY '~6'54 
When HIT is suspected, laboratory tests for the 
presence of heparin-dependent platelet antibodies 
should be performed. 
Laboratory Tests for HIT 
A large number of laboratory tests for heparin 
dependent platelet antibodies have been 
described. 8'14'16'39'42'48"64'74"99-103 Warkentin and Kel- 
ton 9 divided these tests into three groups. Group I 
assays measure a platelet dependent endpoint such as 
aggregation, serotonin release or platelet factor III 
activity initiated by test serum and heparin. 16'39"48"99 
Group II tests measure he~arin dependent binding of 
IgG to normal platelets. 14'42'64"1°° Group III assays 
measure heparin dependent binding of patient IgG to 
individual platelet glycoproteins. 8°'1°1 In clinical prac- 
tice only three methods are commonly used: platelet 
aggregometry, 14C-serotonin release and platelet asso- 
ciated IgG tests. The most frequently used test is the 
aggregation of normal donor platelets by patient 
serum or plasma in the presence of heparin. This 
method is inexpensive, relatively simple and highly 
specific (>92%). 16 However, the sensitivity of the 
aggregometry assay may vary widely between 40% 
and 80% depending on the donor, whose platelets 
were used in the test. I°4 Therefore, a panel of four or 
more donors should be used in order to improve the 
test sensitivity. The most sensitive and specific test is 
probably the one described by Sheridan et al. 99 It is an 
assay that measures 14C serotonin release from 
washed donor platelets using heat treated patient 
serum in the presence of therapeutic (0.1 U/ml) and 
high (100 U/ml) heparin concentrations. If serotonin 
release occurs at therapeutic but not high heparin 
concentration, the test is positive. The test is negative 
if platelet release occurs at both heparin concentra- 
tions or if it fails to occur. The specificity of the assay 
is about 99% and sensitivity approximately 80%. 
Development ofnew and modification of old assays 
have been reported in the past few years. Greinacher 
et al. 1°5 described a rapid assay based on visual 
evaluation of heparin induced platelet activation in 
microtitre wells. The sensitivity of this new test is 
supposed to be similar to 14C serotonin release and 
superior to platelet aggregometry assay. 1°5 Amiral et 
al. 95 reported an ELISA assay for heparin induced 
antibodies based on their reaction with immobilized 
complex of heparin and platelet factor 4. Visentin et 
91 al. modified this assay and found it remarkably 
sensitive. 
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Table 1. General guidelines for prevention of heparin induced 
heparin thrombocytopenia in patients not previously know to have 
heparin-induced antibodies 
A. Heparin of porcine intestinal origin should preferably be used. 
B. The duration of heparin therapy should be minimised whenever 
possible. 
C. In patients who need prolonged anticoagulation oral 
anticoagulants should be started within 24 h of initial heparin 
therapy. 
D. For DVT prophylaxis and treatment LMW heparin is a better 
choice than unfractionated heparin. 
E. Use pure saline or sodium citrate flushes instead of heparin to 
maintain patency of intravascular catheters. 
F. Obtain a complete blood count before initiation of heparin 
therapy and then platelet count every third day. 
G. If an unexplained ecline in the platelet count of more than 30% 
occurs, a test for the presence of heparin-dependent a tibodies 
should be performed. 
Prevention 
Prevention of HIT in patients previously not known to 
have the disorder is unrealistic, however some guide- 
lines have been developed to minimise the risk of HIT. 
These are summarised in Table 1. The general rule is 
that heparin should be used only in well documented 
cases with clear indication for i.v. anticoagulation. 
Thus, the use of heparin flushes to maintain patency of 
intravascular catheters hould be eliminated, since it 
can be successfully replaced with pure saline or 
sodium citrate flushes, m6 Patients who require pro- 
longed therapeutic anticoagulation, but for different 
reasons cannot take oral anticoagulants should be 
treated with LMW heparin or heparinoid rather than 
unfractionated heparin. In these patients, platelet 
counts should be obtained weekly. Finall)~ it is 
important to remember that thrombembolic complica- 
tions in patients with HIT are often devastating but 
unfortunately can not be predicted by any test. 
Treatment 
The following guidelines have been recommended 
when the platelet count falls 30% or moreg: (a) repeat 
platelet count; (b) investigate for other possible causes 
of thrombocytopenia; (c) perform assay of heparin- 
dependent antibodies; (d) re-evaluate the need for 
heparin treatment. It may not be necessary to dis- 
continue therapy in cases of mild thrombocytopenia 
with negative tests for heparin-dependent antibodies 
since type I HIT often resolves even with continuation 
of heparin treatment. However, it is difficult to 
differentiate between type I and the early stages of 
type II HIT and therefore, if heparin has to be 
continued it is mandatory to monitor closely the 
patient's condition and perform platelet counts daily. 
If there are any clinical signs of TEC or if laboratory 
tests indicate type II HIT, heparin therapy should be 
discontinued immediately and alternative therapy 
should be considered. Some authors 56 recommend 
reversal of heparin with protamine sulfate, but in the 
majority of patients, cessation of heparin results in 
rapid recovery of the platelet count. If the patient's 
condition requires continuation of anticoagulation, 
substitution with vitamin K antagonist has been 
recommended. 9"13'21'23'35'41'49'96 Sometimes other ther- 
apeutic modalities must be employed in the interim 
period before anticoagulants become ffective. Several 
agents such as LMW heparin, heparinoids, synthetic 
thrombin inhibitors, Dextran, Iloprost, acetylsalicylic 
acid, sulfinpyrazone, Ancrod, plasmapheresis, mmu- 
noglobulin and fibrinolytic therapy have been used 
with variable results. Although, the optimal therapy 
for patients with HIT remain uncertain, some of the 
drugs which have been used for treatment of HIT are 
reviewed below. 
Low molecular heparin and heparinoids 
There has been a growing interest in treatment of HIT 
with LMW heparin and heparinoids. The clinical 
42 58.61 66 67 83 88 107 110 outcome has been variable. ' . . . . . .  - In the 
cases with a negative cross-reactivity est in vitro, the 
clinical outcome was favourable, but a positive plate- 
let aggregation test was sometimes associated with 
unfavourable clinical outcome. 6~'1°7 The cross reac- 
tivity rate of different LMW heparin preparations 
varies between 25 and 90% 63,66,67 The heparinoid Org 
10172 has not been found to promote heparin-induced 
non-immune aggregation and has shown a low 
frequency (10%) of cross-reactivity in vitro with sera 
containing heparin-dependent antibodies. 58'66'67'111-113 
Magnani reviewed international'experience with the 
use of Org 10172 in 230 patients with HIT for which 
urgent anticoagulation was necessary. 67Ninety-three 
percent of patients adequately responded to Org 
10172, nevertheless, the mortality rate was 26% of 
which 3% was directly attributed to Org 10172 use. 
Experience with Org 10172 is still limited and the 
results of prospective, randomised studies should be 
made available before Org 10172 can be recommended 
as a treatment of choice for the patients with HIT. 
Antiplatelet agents 
Antiplatelet agents uch as aspirin, dipyridamole and 
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dextran block the second phase of platelet aggrega- 
tion. Aspirin has been utilised with some success in 
treatment of HIT 96'114'115 and as a prophylaxis against 
HIT when patients need to be re-exposed to hepa- 
rin. 23'39"116'117 Several investigators have reported 
quicker and safer recovery in patients treated with 
aspirin or dextran. 96"114'11s Iloprost, a prostacyclin 
analogue with half-life of 15-20 rain has been success- 
fully used for treatment of patients with HIT requiring 
re-exposure to heparin. 39'97"~18 
Defibrinogenating agents 
The snake venom Ancrod is a defibrinogenating a ent 
with rapid onset of anticoagulant activity. Ancrod acts 
enzymatically to cleave fibrinogen to split off fibrino- 
peptide A but not fibrinopeptide B, to produce 
unstable non-cross-linked fibrin which is rapidly 
lysed. It lacks immunological cross-reactivity with 
heparin and is relatively simple to monitor by measur- 
ing the fibrinogen level. 34 Ancrod antidote is available 
and restores plasma fibrinogen levels within an 
hour. 119 This agent has been successfully used in 
Canada and the United States for patients who require 
rapid anticoagulation, open heart surgery or vascular 
surgery. ~9,12° 
Other therapies 
Although controversial, streptokinase and urokinase 
treatment has been successful in several cases of HIT 
with TEC. 51'61A21-123 Plasmapheresis has been used in 
a few patients with HIT and thrombosis. 124 The aim of 
this procedure is to remove circulating heparin- 
dependent IgG but it is unclear if such treatment can 
significantly improve the clinical outcome. One case of 
type II HIT with gastrointestinal bleeding treated 
successfully with immunoglobulin has been 
reported. 12s However, it was unclear if recovery was 
due to immunoglobulin fusion or solely cessation of 
heparin treatment. Finall)~ patients with type II HIT 
requiring a haemodialysis have been treated with the 
synthetic thrombin inhibitor Argatroban. 126'127 Arga- 
troban shows no cross-reactivity with heparin- 
dependent antiplatelet antibodies and inhibits hepa- 
rin-induced platelet aggregation. 126 Platelet 
transfusions ometimes used for treatment of HIT 
with bleeding complications ~28 are generally not rec- 
ommended as acute arterial thrombosis can 
Occur .  48,52 
Treatment of HIT with Thromboembolic 
Complications 
When HIT with acute thrombosis i  diagnosed, hepa- 
rin treatment should be immediately discontinued. 
The treatment of choice for arterial thrombosis should 
be surgical. 34 Heparin should not be used perioper- 
atively, but dextran and/or aspirin alone or in 
combination with dipyridamole is recommended. 
Oral anticoagulant treatment should be given as soon 
as possible. Iloprogt perioperatively or Ancrod man- 
agement in an interim period may also be con- 
sidered. 6°'12° The experience of several investigators 
indicates that if heparin is given during operation for 
HIT thrombosis, the procedure fails, whereas patients 
not re-exposed to heparin usually have a successful 
9 21 60 outcome. ' ' Streptokinase orurokinase treatment of 
arterial thrombosis in patients with HIT has been used 
successfully in the number of patients. 9'51'121 Throm- 
bolytic therapy should be also considered for the 
treatment of extensive deep venous thrombosis with 
pulmonary embolism, s1"61'12~'122 
Management of Patients who Require 
Re-exposure to Heparin 
Traditionally all patients undergoing cardiopulmon- 
ary bypass, carotid endarterectomy, femorodistal 
bypass operation and haemodialysis are given hepa- 
rin. Patients with a history of HIT have a higher risk 
for postoperative morbidity and mortality and there- 
fore benefits of surgery should be carefully balanced 
against he risk of potentially dangerous exposure to 
heparin. The experience from several centres indicates 
that patients without demonstrable heparin-depend- 
ent IgG usually tolerate a short re-exposure to hepa- 
rin. 9'96 Heparin treatment in such cases should be 
limited as much as possible and heparin flushes as 
well as heparin coated catheters hould not be used. 
Patients requiring urgent cardiac or vascular sur- 
gery despite circulating heparin-dependent IgG repre- 
sent a difficult clinical problem. Preoperative admini- 
stration of aspirin and dipyridamole 116'117'128 or 
intraoperative infusion of Iloprost 97'118'128'129 allowed 
successful operation in several reported cases. Kappa 
et al. suggested that Iloprost is both safer and more 
effective than aspirin in treatment of these patients. 97 
Ancrod has been used as an alternative to heparin in 
patients with HIT requiring surgery. The reported 
119 120 130 experiences are encouraging. ' ' LMW heparin 
and particularly Org 10172 alone have also been used 
successfully in cases where cross-reactivity in vitro was 
not found. 66'67'131 
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The incidence of HIT in patients requiring haemo- 
dialysis is unknown. These patients are frequently re- 
exposed to heparin and occurrence of HIT could be a 
significant clinical problem. There are a few reports on 
successful treatment of these patients with aspi- 
rin, 132-134 p rostacyclin, 135 Org 1017293"94'136 and Argo- 
troban. 126'127 In some cases heparin free haemodialysis 
has been used.  133'135'137 
Deep vein thrombosis in pregnancy is one of the 
situations where prolonged treatment with heparin is 
often required. A few cases of HIT in pregnancy have 
been reported. 67'13s-141 In two patients, HIT resolved 
after changing to a different brand of heparin, 13s'14° 
another patient developed recurrent HIT after pro- 
longed treatment with Org 10172.142 Van Besien et 
al. ~42 recommended that pregnant patients with HIT 
should be treated with Org 10172 only in the first 
trimester, in the second and third trimester they could 
be treated with oral anticoagulants with minimal 
risks. 143 
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